|Mr. John Peter McLaughlin J.D.||CEO, Pres & Director||N/A||N/A||65|
|Mr. Peter S. Garcia||VP & CFO||N/A||N/A||55|
|Mr. Steffen Pietzke CPA||VP of Fin. & Chief Accounting Officer||N/A||N/A||45|
|Mr. Christopher L. Stone J.D.||VP, Gen. Counsel & Sec.||N/A||N/A||53|
|Mr. Danny J. Hart Jr., J.D.||VP of Bus. Devel.||N/A||N/A||41|
PDL BioPharma, Inc. acquires and manages companies, products, royalty agreements, and debt facilities in the biotech, pharmaceutical, and medical device industries in the United States, Europe, and internationally. The company operates through two segments, Income Generating Assets and Product Sales. The Income Generating Assets segment consists of royalties from issued patents covering the humanization of antibodies, including Avastin, Herceptin, Xolair, Lucentis, Perjeta, Kadcyla, and Tysabri; and notes and other long-term receivables, royalty rights, hybrid notes/royalties receivable, and equity investments in healthcare companies. The Product Sales segment, through its equity and loan investments, manufactures, markets, and sells prescription pharmaceutical products under the Tekturna and Tekturna HCT names in the United States; and Rasilez and Rasilez HCT names internationally for the treatment of hypertension. This segment sells its products primarily to wholesalers. The company was formerly known as Protein Design Labs, Inc. and changed its name to PDL BioPharma, Inc. in 2006. PDL BioPharma, Inc. was founded in 1986 and is headquartered in Incline Village, Nevada.
PDL BioPharma, Inc.’s ISS Governance QualityScore as of September 1, 2017 is 5. The pillar scores are Audit: 1; Board: 3; Shareholder Rights: 5; Compensation: 8.